Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T17:37:04.310Z.
Calculation as of: 2026-10-06T17:37:04.310Z.
Quote observation: 2026-10-06T17:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$1.41B
EV/FCF Ratio
72.60x
TTM Avg
54.11x
3Y Avg
63.60x
5Y Avg
65.58x
Market Cap
$1.41B
EV/FCF Ratio
85.68x
TTM Avg
263.63x
3Y Avg
263.63x
5Y Avg
163.80x
Market Cap
$1.43B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 72.60x | 54.11x | 63.60x | 65.58x |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 85.68x | 263.63x | 263.63x | 163.80x |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.43B | N/A | 4.64x | 4.64x | 4.64x |
| Certara, Inc. (CERT)vs › | $1.43B | 25.02x | 17.90x | 31.06x | 41.90x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 8.62x | 9.15x | 21.82x | 100.71x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
